VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
Cytovance Biologics®, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its mammalian cell culture ...
TG-MVATM uses a scalable cell line manufacturing process intended to strengthen and diversify global mpox and smallpox vaccine supply ...
KATY, TX / ACCESS Newswire / July 6, 2026 / In the fields of life sciences and pharmaceutical R&D, primary cells retain original genetic characteristics and highly restore physiological activities in ...
In June 2026, the hydrogen energy transportation equipment sector in the Xixian New Area saw new progress. A Skyworth-brand hydrogen fuel cell low-floor city bus, with its hydrogen core power system ...
Engineered from the genomes of multiple butterfly species, Chrysalis transposase achieves fast cell recovery, stable expression over 60 cellular generations, and high expression across transgenes. In ...
Intravacc offers four complementary vaccine development platforms: bacterial vaccines, viral vaccines, conjugate vaccines, and E.coli expressed ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...
In a world first Australian researchers will test a one-off therapy that could repair damaged brain cells in people with ...
Recently, the local economic development zone released the pre-approval public notice on the EIA report for the annual 10,000 ...
Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results